β-Glucans and the Metabolic Syndrome - a Human Intervention Study Under BEST

The aim of this study is to investigate the potential disease preventive effects of β-glucans from oat and barley.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Other: no β-glucan; Other: oat β-glucan; Other: barley β-glucan; Other: mutant-barley β-glucan

Detailed Description

Objective:

The primary aim is to examine whether consumption of oat and two different barley β-glucans exhibits hypocholesterolemic effects and to understand the underlying mechanisms.

Secondary aims are to investigate whether there are also effects on blood pressure, appetite regulation, insulin sensitivity, hemostasis, low-grade inflammation and the metabolic profile of different biological materials.

Intervention:

In each of the 4 intervention periods the participants drink a milk drink together with their three main meals for 21 days. This way they consume 5g β-glucan/d form either oat or barley in the three treatment periods, otherwise they maintain their habitual diet. They are not, however, allowed to eat any oat- or barley-containing products during the trial.

At the beginning and at the end of each intervention period the participants' blood pressure is measured and a fasting blood sample is drawn.

Further they collect feces for 72 hours and urine for 24 hours before and at the end of each intervention period.

Before and at the end of each intervention period a 4-hour meal test is undertaken to measure their subject appetite sensation. Here at first a fasting blood samples drawn and thereafter the milk drink is served. Appetite sensation is assessed every 30 min for 4 hours. Also blood samples are drawn at 2 hours and 4 hours at the meal tests which takes place before each intervention period.

At the subsequent "ad libitum" lunch meal the food intake is measured and then a final appetite registration is made.

Furthermore participants make 4-d food records before and at the end of each intervention period.

• Study Type: Interventional
• Enrollment (Anticipated): 16
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Denmark
  • Copenhagen, Denmark, 1165
    • University of Copenhagen

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 40 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• normal weight or moderately overweight (BMI 18.5-30 kg/m²)

Exclusion Criteria:

• chronic diseases (e.g. diabetes, cardiovascular disease)
• elevated blood pressure
• hyperlipidemia
• consumption of dietary supplements during or 2 month prior to start of study (including vitamin tablets)
• consumption of oat and barley products from January 1st until the end of study
• smoking
• excess physical activity (> 8h/week)
• medicine use (not included contraceptives or occasional pain killer consumption)
• pregnancy
• breast feeding

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Double

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo milk drink	Other: no β-glucan; daily consumption of non-β-glucan containing milk drinks together with the 3 main meals for 21 days
Experimental: Millk drink with oat β-glucan	Other: oat β-glucan; daily consumption of 5g of oat β-glucan in the form of milk drinks with the 3 main meals for 21 days; Other Names: "PromOat",Biovelop, Kimstad, Sweden
Experimental: Milk drink with barley β-glucan	Other: barley β-glucan; daily consumption of 5g β-glucan extracted from the barley-mutant mother "Bomi" in the form of milk drinks with the 3 main meals for 21 days
Experimental: Milk drink with mutant-barley β-glucan	Other: mutant-barley β-glucan; daily consumption of 5g β-glucan extracted from the high β-glucan barely mutant "lys. 5.f" in the form of milk drinks with the 3 main meals for 21 days

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
change in total and LDL cholesterol concentration	fasting blood sample at baseline and day 21
pH, SCFA, bile acids, total fat, total energy, cholesterol (in 72h feces)	average over three days at baseline and after 3 weeks
weight	at baseline and after 1, 2 and 3 weeks
food intake (in 4d records)	at baseline and after 3 weeks
height	at baseline

Secondary Outcome Measures

Outcome Measure	Time Frame
insulin, glucose, IL-6, CRP, TNF-α, fibrinogen, PAI-1, appetite regulation peptides, alkylresorcinol, metabolomics (in fasting and meal test blood samples)	fasting blood sample at baseline and on day 21
appetite sensation (in meal tests)	3h appetite registrations at baseline and on day 21
metabolomics, isoprostanes (in 24h urine)	at baseline and after 3 weeks
metabolomics (in 72h feces)	average over 3 days at baseline and after 3 weeks
blood pressure	at baseline and on day 21

Collaborators and Investigators

• Sponsor: University of Copenhagen
• Investigators: Principal Investigator: Arne Astrup, Professor, Department of Human Nutrition, University of Copenhagen

Study record dates

Study Major Dates

• Study Start: November 1, 2009
• Primary Completion (Actual): October 1, 2010
• Study Completion (Actual): March 1, 2011

Study Registration Dates

• First Submitted: March 11, 2011
• First Submitted That Met QC Criteria: March 16, 2011
• First Posted (Estimate): March 17, 2011

Study Record Updates

• Last Update Posted (Estimate): March 17, 2011
• Last Update Submitted That Met QC Criteria: March 16, 2011
• Last Verified: November 1, 2009

More Information

Terms related to this study

• Keywords: appetite; blood glucose; bile acids; cholesterol; β-glucan
• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Insulin Resistance; Hyperinsulinism; Metabolic Syndrome
• Other Study ID Numbers: M196